Miwa Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Miwa Ito has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Takekawa
Cardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, Japan
1 shared publication - Honsa Kang
Cardiovascular Centre, Fukuoka City Hospital , 13-1 Yoshizukahon-machi, Hakata-ku, Fukuoka 812-0046
1 shared publication - Keiichi Ashikaga
Miyazaki Medical Association Hospital Cardiovascular Center, Japan (K.A., M. Ito)
1 shared publication - Kengo Ayabe
Cardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, Japan
1 shared publication - Tomoyoshi Komiyama
Affiliation Department of Clinical Pharmacology, Tokai University School of Medicine, Isehara, Kanagawa, Japan
1 shared publication - Yasuaki Tsumagari
Cardiovascular Center, Miyazaki Medical Association Hospital, Miyazaki 880-2102, Japan
1 shared publication
Latest Publications
- Open Access
Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
Landiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. Hence, this study aimed to evaluate the effectiveness of landiolol in patients with atrial fibrillation (AF) and atrial tachycardia (AT), not limited to those with heart failure with a reduced ejection fraction. To this end, we evaluated the efficacy and safety of landiolol in managing tachycardiac AF and tachycardiac atrial flutter/AT in 44 patients with reduced left ventricular function. We found that while landiolol was effective in managing patients with AF and heart failure with a preserved or mid-range ejection fraction, however, it might be more challenging to control heart rate in patients with AT using a similar dosage of landiolol.
Open AccessDifferential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
Landiolol, an ultra-short-acting β1-selective blocker, is more effective in controlling heart rate compared with digoxin in patients with atrial tachyarrhythmias and left ventricular dysfunction. However, the effect of atrial tachyarrhythmia type on the effectiveness of landiolol remains unknown. Hence, this study aimed to evaluate the effectiveness of landiolol in patients with atrial fibrillation (AF) and atrial tachycardia (AT), not limited to those with heart failure with a reduced ejection fraction. To this end, we evaluated the efficacy and safety of landiolol in managing tachycardiac AF and tachycardiac atrial flutter/AT in 44 patients with reduced left ventricular function. We found that while landiolol was effective in managing patients with AF and heart failure with a preserved or mid-range ejection fraction, however, it might be more challenging to control heart rate in patients with AT using a similar dosage of landiolol.